Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Asset Writedowns and Impairment (2024 - 2025)

Kymera Therapeutics (KYMR) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $45000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $45000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 million, a 20.81% decrease, with the full-year FY2025 number at $3.9 million, down 20.81% from a year prior.
  • Asset Writedowns and Impairment was $45000.0 for Q4 2025 at Kymera Therapeutics, down from $3.9 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $4.9 million in Q1 2024 to a low of $45000.0 in Q4 2025.